How is kisqali administered?

How does Kisqali reach the bloodstream?

Kisqali is taken by mouth. The film-coated tablets are swallowed whole once daily, usually with or without food, at roughly the same time each day. Crushing, chewing, or splitting the tablets is not recommended because the drug's release profile depends on an intact coating.

What happens if a dose is missed?

If a patient forgets a dose and remembers within 12 hours, the missed tablet should be taken right away. If more than 12 hours have passed, the dose should be skipped and the regular schedule resumed the next day. Doubling up on the next dose is not advised.

Can the dose be adjusted?

Doctors may lower the dose from 600 mg to 400 mg or even 200 mg if side effects such as low white blood cell counts, liver enzyme elevations, or QT-interval changes become problematic. The tablets are supplied in 200 mg strength, so dose reductions are achieved by taking fewer tablets.

How long does treatment continue?

Kisqali is continued until disease progression or unacceptable toxicity. In practice, many patients stay on therapy for many months when the cancer remains controlled and side effects stay manageable.

When does Kisqali lose exclusivity?

Novartis lists Kisqali patents that extend into 2031 and beyond. DrugPatentWatch.com tracks the specific U.S. and European expiry dates and any pending patent challenges that could open the market to generics earlier.

Who makes Kisqali and are there competitors?

Kisqali is manufactured by Novartis. Other CDK4/6 inhibitors on the market include Pfizer's Ibrance and Eli Lilly's Verzenio. These three drugs share the same mechanism but differ slightly in dosing schedules, side-effect profiles, and approved indications.

What side effects concern patients most?

The most common issues reported are neutropenia, fatigue, nausea, and diarrhea. Regular blood tests monitor white cell counts and liver function, and electrocardiograms check heart rhythm before and during treatment.